News Releases

Year

25 Mar '21

Cortexyme to Present at the Stifel 3rd Annual CNS Day on April 1, 2021

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Mar. 25, 2021-- Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer's disease with topline data expected in the fourth quarter of 2021 and a growing pipeline of therapeutics for degenerative diseases, today announced Casey

PDF Version

10 Mar '21

Cortexyme to Present at the Oppenheimer 31st Annual Healthcare Conference on March 16, 2021

-- Presentation to be webcast on Cortexyme’s website -- SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Mar. 10, 2021-- Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company focused on Alzheimer’s and other degenerative diseases, today announced Chris Lowe , the company’s chief

PDF Version

08 Mar '21

Cortexyme Announces Partnership with Parkinson Study Group and Upcoming Alzheimer’s Disease Data Presentation

-- Partnership with Parkinson Study Group Advisory Panel to collaborate on Parkinson’s Disease Program -- -- Presentation at AD/PD™ 2021 Underscores Relevance of Cortexyme’s Approach -- SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Mar. 8, 2021-- Cortexyme, Inc.

PDF Version

15 Feb '21

Cortexyme Provides Regulatory Update on Development Program for Atuzaginstat in Alzheimer’s Disease

- Double-blind phase of GAIN Trial to continue as planned, with top-line data expected Q4 2021 - Open-Label Extension of atuzaginstat to stop dosing and enrollment SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 15, 2021-- Cortexyme, Inc. (NASDAQ: CRTX), a clinical-stage biopharmaceutical

PDF Version

10 Feb '21

Cortexyme Announces Leadership Appointments to Support Advancement of Atuzaginstat and Pipeline Expansion

— Chris Lowe Promoted to Chief Operating Officer and Chief Financial Officer — Ted Monohon Promoted to Chief Accounting Officer —Drew Sukovich, Ph.D., RAC, Joins as Vice President, Regulatory and Quality SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 10, 2021-- Cortexyme, Inc.

PDF Version

26 Jan '21

Cortexyme Announces Pipeline Update and Anticipated 2021 Milestones

— Based upon successful completion of the GAIN Trial’s interim analysis, pipeline expansion announced for 2021 — Atuzaginstat to be studied in the PEAK trial, a new Phase 2 study for Parkinson’s disease — COR588, a novel lysine gingipain inhibitor, on track to enter the clinic in Q3 2021 — Top-line

PDF Version